Results 11 to 20 of about 742,291 (286)
PARP inhibitors for cancer therapy
Expert Reviews in Molecular Medicine, 2005 Poly(ADP-ribose) polymerase 1 (PARP-1) is a zinc-finger DNA-binding enzyme that is activated by binding to DNA breaks. Poly(ADP-ribosyl)ation of nuclear proteins by PARP-1 converts DNA damage into intracellular signals that activate either DNA repair by the base-excision pathway or cell death. A family of 18 PARPs has been identified, but only the most
Curtin NJ
core +8 more sources
PARP inhibitors in ovarian cancer: evidence, experience and clinical potential
Therapeutic Advances in Medical Oncology, 2017 Inhibitors of poly(ADP-ribose) polymerase (PARP) are considered one of the most active and exciting new therapies for the treatment of ovarian cancer.
Tarra Evans, Ursula Matulonis
doaj +2 more sources
PARP inhibitors in ovarian cancer [PDF]
Annals of Oncology, 2016 Slow progress in improving the outcome of ovarian cancer with chemotherapy over the last decade has stimulated research into molecularly targeted therapy. Poly(ADP-ribose) polymerase (PARP) inhibitors target DNA repair and are specifically active in cells that have impaired repair of DNA by the homologous recombination (HR) pathway.
Ledermann, JA
openaire +5 more sources
A Review on DNA Repair Inhibition by PARP Inhibitors in Cancer Therapy
Folia Medica, 2018 The DNA repair process protects the cells from DNA damaging agent by multiple pathways. Majority of the cancer therapy cause DNA damage which leads to apoptosis.
Shah Ashish P. +3 more
doaj +2 more sources
Hereditary Cancer in Clinical Practice, 2015 بوليميرازات بولي (ADP - ريبوز)، التي يتم اختصارها باسم PARPs، هي مجموعة من البروتينات المألوفة التي تلعب دورًا مركزيًا في إصلاح الحمض النووي باستخدام مسار إصلاح استئصال القاعدة (BER). هناك حوالي 17 بروتينًا في هذه العائلة منها PARPs النووية الأولية هي PARP -1 و PARP -2 و PARP -3 و tankyrases 1 و 2 (PARP -5a و -5b).
Maheen Anwar +2 more
+8 more sources
Advances in the use of PARP inhibitor therapy for breast cancer [PDF]
Drugs in Context, 2018 Poly-ADP-ribose polymerase 1 (PARP-1) and PARP-2 are DNA damage sensors that are most active during S-phase of the cell cycle and that have wider-reaching roles in DNA repair than originally described.
Kelly E McCann, Sara A Hurvitz
doaj +2 more sources
PARP inhibitors: the race is on [PDF]
British Journal of Cancer, 2016 Since the seminal publications in 2005 that demonstrated the exquisite sensitivity of BRCA1 and BRCA2 (BRCA1/2) mutant cell lines and xenografts to poly(ADP-ribose) polymerase (PARP) inhibition (Bryant et al, 2005; Farmer et al, 2005), the race has been on to exploit single-agent PARP inhibitors for clinical use through the concept of tumour-specific ...
Brown, Jessica S +2 more
openaire +2 more sources
Annals of Internal Medicine: Clinical Cases, 2023 Poly (ADP-ribose) polymerase (PARP) inhibitors are approved for the treatment of several types of cancers. We report a case of an 80-year-old Japanese woman who developed drug-induced interstitial lung disease (ILD) during treatment with PARP inhibitors (
Hiroshi Sugimoto +5 more
doaj +1 more source
Frontiers in Pharmacology, 2023 Background: Since its discovery, poly (ADP-ribose) polymerase 1 (PARP-1) has been extensively studied due to its regulatory role in numerous biologically crucial pathways.
Wen-Hao Li +6 more
doaj +1 more source
Perspectives on PARP Inhibitor Combinations for Ovarian Cancer
Frontiers in Oncology, 2021 Poly (ADP-ribose) polymerase (PARP) inhibitors constitute an important treatment option for ovarian cancer nowadays. The magnitude of benefit from PARP inhibitors is influenced by the homologous recombination status, with greater benefit observed in ...
Renata Colombo Bonadio +3 more
doaj +1 more source